There is a clear need for long-term studies in women without PCOS, to assess the impact of GLP-1 RA medications in a dose-response manner on reproduction to evaluate their safety since many women of reproductive age are resorting to these medications without knowing whether they could have any negative impact on their future fertility. This evidence concerns the gene GCG and polycystic ovary syndrome.